Rhythm Pharmaceuticals (NASDAQ: RYTM) CAO exercises options, sells shares

Rhea-AI Filing Summary

Rhythm Pharmaceuticals corporate controller Christopher Paul German reported option exercises and share sales. On March 4, 2026, he exercised stock options for 1,500 shares at an exercise price of $17.97 per share, converting derivative awards into common stock.

That same day, he sold 5,614 shares of common stock in open-market transactions at $89.56 per share, leaving 160 shares of common stock held directly after the sale. A footnote notes that his holdings include 21 shares purchased through the employee stock purchase plan and that the options vest in scheduled installments through March 20, 2027.

Insider Trade Summary

Net Seller: 5,614 shares ($502,790)

Net Sell 3 txns

Insider German Christopher Paul

Role Corporate Controller & CAO

Sold 5,614 shs ($503K)

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	1,500	$0.00	--
Exercise	Common Stock	1,500	$17.97	$27K
Sale	Common Stock	5,614	$89.56	$503K

Holdings After Transaction: Stock Options (Right to Buy) — 3,731 shares (Direct); Common Stock — 5,753 shares (Direct)

Footnotes (1)

1. Includes 21 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan. The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

German Christopher Paul

(Last) (First) (Middle)

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Corporate Controller & CAO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M		1,500	A	$17.97	5,753	D
Common Stock	03/04/2026		S		5,614	D	$89.56	160(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$17.97	03/04/2026		M			1,500	(2)	04/03/2033	Common Stock	1,500	$0	3,731	D

Explanation of Responses:

1. Includes 21 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan.

2. The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did RYTM’s Christopher Paul German report?

Christopher Paul German reported exercising options for 1,500 Rhythm Pharmaceuticals shares and selling 5,614 common shares in open-market trades at $89.56 per share, leaving 160 shares held directly after the transactions, according to the Form 4 filing details.

How many Rhythm Pharmaceuticals (RYTM) shares did the insider sell?

The insider sold 5,614 shares of Rhythm Pharmaceuticals common stock. These sales were reported as open-market or private transactions at a price of $89.56 per share, with the filing showing 160 shares of common stock remaining in his direct ownership afterward.

What stock options did the Rhythm Pharmaceuticals insider exercise?

He exercised stock options covering 1,500 shares of Rhythm Pharmaceuticals common stock at an exercise price of $17.97 per share. The options were originally granted on April 4, 2023, and vest in scheduled installments through March 20, 2027, subject to continued service.

What is Christopher Paul German’s role at Rhythm Pharmaceuticals (RYTM)?

Christopher Paul German serves as Corporate Controller and Chief Accounting Officer at Rhythm Pharmaceuticals. His Form 4 filing reports his personal option exercises and share sales, reflecting changes in his direct ownership of the company’s common stock on March 4, 2026.

How many Rhythm Pharmaceuticals shares does the insider own after these trades?

After the reported transactions, the filing lists 160 shares of Rhythm Pharmaceuticals common stock as held directly by the insider. A footnote states that his holdings include 21 shares acquired through the company’s employee stock purchase plan, within this ownership figure.

How do the Rhythm Pharmaceuticals options for this insider vest over time?

The options were granted April 4, 2023 and vest 25% on March 20, 2024. The remaining 75% vests in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, contingent on his continued service at each vesting date.